Out of 313 patients with invasive sBBCs, most of the tumors were luminal (n = 538, 87.6%), whereas triple-negative breast cancer (TNBC) (n = 44, 7.2%) and HER2+ breast cancers (n = 32, 5.2%) were rare (Supplementary Table 2). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.